Nykode Therapeutics (NYKD) Q4 2024 earnings summary

Executive summary

• Strategic refocus and organizational restructuring implemented, including layoffs and cost reductions, to align activities and cash burn with a cash runway extending into 2030 and a targeted annual cost base of $20 million.

• Strong cash position of $115.4 million at year-end 2024, supporting long-term sustainability.

• Regained full ownership and IP rights to VB10.NEO, enabling new partnership opportunities.

• Published final Phase 2 data for VB10.16, confirming prolonged benefit and vaccination effect in advanced cervical cancer.

• Presented new preclinical data for the APC-targeted immune tolerance platform at a major industry conference.

Financial highlights

• Q4 2024 revenue was $6.9 million, up from $2.3 million year-over-year, mainly due to the Genentech agreement termination.

• Q4 2024 net loss was $6.8 million, compared to $5.3 million in Q4 2023; full-year net loss was $38.8 million.

• Employee benefit and other operating expenses decreased year-over-year due to organizational reduction and lower R&D activity.

• Equity ratio at year-end was 89%, with total equity of $136.2 million.

• Cash and cash equivalents at year-end: $115.4 million (2023: $162.6 million).

Outlook and guidance

• Annual cost base targeted at $20 million, expected to be reached in 2026, extending cash runway into 2030.

• Pipeline priorities include executing the VB10.16 C-03 trial, determining the path for VB10.NEO, and optimizing the immune tolerance platform.

• Further guidance on VB10.NEO's path and partnership strategy expected in the first half of 2025.

• Continued pursuit of early partnerships and collaborations, especially for the immune tolerance platform.

• News flow from Regeneron programs subject to partner approval.